NeXstar Applies Balm From Gilead
Gilead Sciences began with, and then got rid of, programs in antisense in order to concentrate on nearer-term projects. NeXstar, too, tried to get rid of its oligonucleotide research by spinning it off into a separate company so as not to drag down the earnings of its product business. The market didn't care--and NeXstar chose to sell when Gilead came calling. Now Gilead's come full circle: With its acquisition of NeXstar, it's back into oligonucleotide research.
You may also be interested in...
FDA concluded that original formulation of brain hemorrhage treatment was not discontinued for safety or effectiveness reasons, saying Arbor had other options to reduce risk of confusion between the new and original formulations. But the sponsor argues that withdrawal was part of FDA-approved risk mitigation plan.
Despite AI and digital analytics playing an increasing role in pharma, the industry lags others globally, a recent event heard. Meanwhile, top Indian players including Sun Pharma, Cipla and others shared what is driving their initiatives, ranging from a 'touchless factory' to virtual training and lessons learned along the way.
Hologic made its third big acquisition of 2021 and Agilent agreed to pay up to $695m for Resolution Bioscience to extend its precision oncology capabilities.